New study probes how pirtobrutinib alters immune cells in blood cancer

NCT ID NCT07428707

Recruiting now Knowledge-focused Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This early-phase study is testing pirtobrutinib, a drug already approved for later-stage CLL/SLL, in 30 people who have not yet received any treatment. The main goal is to see how the drug changes immune cells in lymph nodes and blood, not to measure cure or symptom relief. Participants take the drug daily in 28-day cycles and undergo biopsies and scans to track immune changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pirtobrutinib
What this could lead to: If successful, this study could reveal how pirtobrutinib reshapes the immune system in early CLL/SLL, potentially guiding better treatment strategies.
What could go wrong: This is a very early, small study (30 people) focused on immune profiling, not on proving treatment effectiveness. Results may not lead to direct clinical benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.